Mirum (MIRM) news
Recent news
Mirum Pharmaceuticals: Morgan Stanley cuts target price to $137.00 from $150.00
AInvest Wire · Aug 6, 2026MIRUM PHARMACEUTICALS, INC.: H.C. Wainwright cuts target price to $140 from $185
H.C. Wainwright has revised its price target for Mirum Pharmaceuticals (NASDAQ:MIRM), reducing it to $140 from a previous $185 while maintaining its "Buy" rating for the stock. This adjustment reflects updated expectations for the company’s growth trajectory and valuation. The firm cited interim…
AInvest Wire · Aug 6, 2026MIRUM PHARMACEUTICALS, INC.: JP Morgan cuts target price to $118 from $125
AInvest Wire · Aug 6, 2026Mirum Pharmaceuticals Q2 operating income USD -42.537 million
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) reported an operating loss of $42.537 million for the second quarter of 2023, reflecting continued investment in its pipeline of therapies for rare liver diseases. The company’s total revenue for the quarter reached $37.5 million, driven by $32.5 million…
AInvest Wire · Aug 5, 2026Mirum Pharmaceuticals reports inducement grants under Nasdaq listing rule 5635(c)(4)
Mirum Pharmaceuticals Inc. (NASDAQ: MRM) has disclosed inducement grants made to new employees and directors in compliance with Nasdaq Listing Rule 5635(c)(4). The grants, which include stock options and restricted stock units, were approved by the company’s board of directors and are intended to…
AInvest Wire · Jun 11, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.